fda warning letters compounded semaglutide october 2025 September 8, 2025: launches an import alert listing safe GLP-1 manufacturers – Partnership for Safe Medicines fda glp-1 compounding warning letters

Your first week is not the time to prove discipline

Protein is one of the strongest direct triggers of GLP-1 release, says Dr Jean-Marc Sobczyk, naturopathic doctor at Hooke

Its unique action as a GLP-1 agonist allows it to activate not only GLP-1 but also GIP receptors, enhancing its benefits for people with type 2 diabetes

(U.S.) Zealand Pharma A/S (Denmark) Takeda Pharmaceutical Company Limited (Japan) Structure Therapeutics Inc

Semaglutide can also lead to similar issues but may be milder for some users

To validate these findings, multiple sensitivity analyses were carried out using a variety of selection criteria and models that integrated various covariates (Table S7)